Purchase this article with an account.
Carlo E. Traverso, Marina Papadia, Alessandro Bagnis, Riccardo Scotto, Auli M. Ropo, Hannu M. Uusitalo; Post-hoc Analysis Of Pre-trial Medications Effect On IOP Lowering Response Of Two Topical Prostaglandins. Invest. Ophthalmol. Vis. Sci. 2011;52(14):233.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate efficacy of tafluprost 0.0015% vs latanoprost 0.005% in relation to prior medication.
Prospective randomized evaluation; pooled data from the two centers participating to the trial.
Sixty-seven patients enrolled: 22 were on PGs, 15 on other glaucoma medications and 30 naïve to therapy. 48 (72 %) had a positive outcome defined as a reduction in IOP of ≥25% . Prior PG users responded more frequently than those with no prior medication (OR 1.71 - not statistically significant). The difference between prior PG and other glaucoma medication users was smaller (OR 1.20). PG users responded (≥25% reduction of IOP) to a similar extent with latanoprost (8/11 patients ) and tafluprost (9/11 patients).
Medical treatment trials often include a wash-out at the initiation of the study. Often patients are recruited irrelevant of prior medical regimen. Although differences in prior treatment did not show statistically significant differences in the results of latanoprost vs tafluprost in our study, the trend of IOP response in patients with prior PG treatment warrants further investigation, which could be useful in the interpretation of data and recommendations for subjects recruitment.
This PDF is available to Subscribers Only